Will third time be the charm? Lex­i­con fi­nal­ly re­files SGLT2 drug for heart fail­ure

Lex­i­con’s ex­per­i­men­tal treat­ment of heart fail­ure is fi­nal­ly on its way to the FDA — again.

The Wood­lands, TX-based biotech says it’s re­sub­mit­ted an NDA to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER